Related Experiment Video
Updated: Dec 4, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease
Syazrah Salam1, Orla Gallagher2, Fatma Gossiel2
1Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom; Academic Unit of Bone Metabolism and Mellanby Centre for Bone Research, University of Sheffield, United Kingdom.
Insights
Vascular calcification (VC) is more severe in advanced chronic kidney disease (CKD) patients, particularly those with diabetes. Higher levels of parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23) are linked to increased VC in CKD.
Area of Science:
- Nephrology
- Endocrinology
- Radiology
Background:
- Vascular calcification (VC) and renal osteodystrophy are significant complications in advanced chronic kidney disease (CKD).
- Lower leg arterial calcification (LLAC) is a quantifiable measure of VC in CKD patients.
- The relationship between LLAC, vascular biomarkers, and bone health in CKD remains unclear.
Purpose of the Study:
- To investigate the association between LLAC and various biomarkers in CKD patients.
- To explore the correlation of LLAC with bone turnover and microstructure.
- To identify independent predictors of LLAC in advanced CKD.
Main Methods:
- Cross-sectional study involving 69 CKD stages 4-5D patients and 68 healthy controls.
- Fasting blood samples analyzed for biomarkers.
- High-resolution peripheral quantitative computed tomography (HRpQCT) assessed bone microstructure.
- Trans-iliac bone biopsy performed on 43 CKD patients.
Main Results:
- LLAC was significantly more severe in CKD patients than controls (p < 0.001).
- CKD patients with diabetes exhibited substantially higher LLAC (p < 0.001).
- LLAC correlated with serum phosphate, calcium x phosphate product, intact parathyroid hormone (iPTH), intact fibroblast growth factor-23 (iFGF23), and bone turnover markers. LLAC also correlated with poorer distal tibia cortical bone mineral density, thickness, and porosity.
- No association was found between LLAC and bone turnover, mineralization, or volume on biopsy.
Conclusions:
- Older age, diabetes, elevated iPTH, and iFGF23 are independently associated with LLAC in advanced CKD.
- These factors may play crucial roles in the development of LLAC.
- LLAC serves as a valuable indicator of vascular complications in CKD.
Background:
Vascular calcification (VC) and renal osteodystrophy are important complications of advanced chronic kidney disease (CKD). High resolution peripheral quantitative computed tomography (HRpQCT) is able to assess bone microstructure in renal osteodystrophy and lower leg arterial calcification (LLAC) is usually seen as an incidental finding. LLAC can be a useful quantitative assessment of VC in CKD but the relationship between LLAC and vascular biomarkers and bone is unknown. We aimed to assess the relationship between LLAC and biomarkers, bone turnover and microstructure.
Methods:
In this cross-sectional study, fasting blood samples were taken from 69 CKD stages 4-5D patients and 68 healthy controls. HRpQCT of distal tibia and radius were performed. 43 CKD patients had trans-iliac bone biopsy after tetracycline labelling.
Results:
LLAC was more severe in CKD than controls (median [IQR] 1.043 [0.05-16.52] vs 0 [0-0.55] mgHA, p < 0.001). CKD patients with diabetes (28%) had significantly higher LLAC compared to non-diabetic CKD (median [IQR] 24.07 [3.42-61.30] vs 0.23 [0-3.78] mgHA, p < 0.001). LLAC mass in CKD correlated with serum phosphate (rho = 0.29, p < 0.05), calcium x phosphate product (rho = 0.31, p < 0.05), intact parathyroid hormone (rho = 0.38, p < 0.01), intact fibroblast growth factor-23 (iFGF23) (rho = 0.40, p = 0.001), total alkaline phosphatase (rho = 0.41, p < 0.001), bone alkaline phosphatase (rho = 0.29, p < 0.05), osteocalcin (rho = 0.32, p < 0.05), osteoprotegerin (rho = 0.40, p = 0.001) and dephosphorylated-uncarboxylated matrix Gla protein (rho = 0.31, p < 0.05). LLAC in CKD also correlated with worse distal tibia cortical bone mineral density, thickness and porosity. No association was found between LLAC and bone turnover, mineralization or volume on biopsy in CKD. In multivariate analysis, only age, diabetes, iPTH and iFGF23 were independently associated with LLAC in CKD.
Conclusions:
High levels of PTH and FGF23, along with older age and the presence of diabetes may all play independent roles in the development of LLAC in advanced CKD.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Skeleton and Calcium Homeostasis
Chronic Kidney Disease IV: Nursing Management

